Hepatic iron quantitation and liver biopsy in sickle cell disease and thalassemia major - impact on monitoring and preventing the progression of iron overload due to regular transfusion therapy.

National Library of Canada - Hepatic iron quantitation and liver biopsy in sickle cell disease and thalassemia major, impact on monitoring and preventing the progression of iron overload due to regular transfusion therapy



Description: -
-Hepatic iron quantitation and liver biopsy in sickle cell disease and thalassemia major - impact on monitoring and preventing the progression of iron overload due to regular transfusion therapy.
-
n:o 21.
Tiedonantoja (Joensuun yliopisto. Yhteiskuntatieteiden tiedekunta) ;
Occasional papers / University of Joensuu, Human Geography and Planning
n:o 21 =
Tiedonantoja / Joensuun yliopisto, Yhteiskuntatieteiden tiedekunta, Historiae naturalis classica -- 10
Canadian theses = -- Thèses canadiennesHepatic iron quantitation and liver biopsy in sickle cell disease and thalassemia major - impact on monitoring and preventing the progression of iron overload due to regular transfusion therapy.
Notes: Thesis (M.Sc.) -- University of Toronto, 2001.
This edition was published in 2001

Tags: #Iron

Iron

Because fecal iron excretion induced by deferiprone is much less than that by deferoxamine,, the short-term efficacy of deferiprone is unquestionably inferior to that of deferoxamine. As noted above, reliance on serum ferritin concentrations alone may lead to inaccurate assessment of body iron burden in individual patients, and direct assessment of changes in tissue iron is particularly crucial in the evaluation of any new chelator. ACS Nano 2021, 15 1 , 419-433.

Physiology and pathophysiology of iron in hemoglobin

In this study on average, patients with Thal began transfusion at 4 years of age, whereas SCD patients began at 13 years. In practice, the approach of most clinicians is to determine the serum ferritin concentration after a period of regular transfusions and, based on the value of this parameter, to begin a regimen of nightly subcutaneous deferoxamine therapy.

Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

Liver disease may result from viral hepatitis and iron overload due to multiple transfusions of blood products or due to disease activity causing varying changes in vasculature. Growth factors have been used in some cases of severe or protracted neutropenia, but their value is uncertain. TS usually remains elevated until iron stores are depleted, whereas ferritin, which may initially fluctuate, eventually begins to fall progressively with iron mobilization and is reflective of depletion of iron stores.

Hepatic iron quantitation and liver biopsy in sickle cell disease and thalassemia major, impact on monitoring and preventing the progression of iron overload due to regular transfusion therapy

The natural extension of this approach is the further development of partnerships between countries where expertise in this field has been developed and adjacent countries where no such expertise exists. Recently, deferasirox Exjade , an orally administered iron-chelating drug, has been approved in the United States for treatment of secondary iron overload due to ineffective erythropoiesis.

Related Books

- Zorka Karađorđević
- Auferweckung als Befreiung - eine Studie zur Passions- und Auferstehungstheologie des Matthäus (bes
- Razor edge of balance - a study of Virginia Woolf.
- Foreman on the assembly line.
- Gabriel Fauré - a guide to research